Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biomea Fusion, Inc.

1.75
+0.06003.55%
Volume:764.92K
Turnover:1.39M
Market Cap:65.75M
PE:-0.46
High:1.97
Open:1.71
Low:1.67
Close:1.69
Loading ...

Company Profile

Company Name:
Biomea Fusion, Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
106
Office Location:
900 Middlefield Road,4th Floor,Redwood City,California,United States
Zip Code:
94063
Fax:
- -
Introduction:
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Directors

Name
Position
Thomas Butler
Chief Executive Officer, Co-Founder and Director
Rainer Erdtmann
President, Chief Operating Officer, Co-Founder and Director
Bihua Chen
Director
Eric Aguiar
Director
John Kwon
Director
Michael J. M. Hitchcock
Director
Sotirios Stergiopoulos
Director

Shareholders

Name
Position
Thomas Butler
Chief Executive Officer, Co-Founder and Director
Rainer Erdtmann
President, Chief Operating Officer, Co-Founder and Director
Sunny Lee Ryan
Executive Vice President of Finance